Cadila jumps 5% on receiving EIR from USFDA for Moraiya unit

Shares of drug firm Cadila Healthcare today rose 5 per cent after the company received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility in Moraiya, indicating "closure of the inspection points".
The stock climbed 4.81 per cent to settle at Rs 359.30 on BSE. During the day, it went up by 6.18 per cent to Rs 364.
On NSE, it soared 4.99 per cent to end at Rs 360.30.
Cadila Healthcare has received EIR from the US health regulator for its manufacturing facility in Moraiya, indicating "closure of the inspection points" of initial review in 2014.

The company's "Moraiya manufacturing facility has received an Establishment Inspection Report from the United States Food and Drug Administration (USFDA)," Cadila Healthcare said in a BSE filing.
This receipt of EIR only indicates closure of the inspection points (483s) raised based on the inspection carried out between August 28, 2014 and September 5, 2014, it added.

"What is 'closed' is the initial review that resulted in the warning letter issuance," Cadila Healthcare said.
Though this is a positive step towards the resolution of the warning letter issued by the USFDA, it does not in itself indicate resolution of the warning letter, it added.

Cadila further said: "The company is in constant follow up with the USFDA for resolution of the warning letter.